Novus Therapeutics to Release Third Quarter 2020 Financial Results on Monday, November 16
Novus Therapeutics, Inc. (NASDAQ: NVUS) will report its financial results for the three and nine months ended September 30, 2020, on November 16, 2020, after market close. The company focuses on developing targeted medicines for organ transplantation and immunological diseases. A corporate update conference call will be held the same day at 4:30 PM ET. Investors and analysts can join via a toll-free number or the provided webcast link.
- Potential growth in targeted medicines development for organ and cellular transplantation.
- Scheduled financial results announcement may enhance market visibility.
- Lack of disclosed financial metrics may create uncertainty among investors.
IRVINE, Calif.--(BUSINESS WIRE)--Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients undergoing organ or cellular transplantation, as well as those living with immunological diseases, today announced that the company will report its financial results for the three and nine months ended September 30, 2020, after the market close on Monday, November 16, 2020. Management will host a corporate update conference call and webcast at 4:30 PM Eastern Time the same day.
Conference Call Details |
||||
Monday, November 16, at 4:30 PM Eastern Time / 1:30 PM Pacific Time |
||||
Toll Free: |
877-407-3982 |
|||
International: |
201-493-6780 |
|||
Conference ID: |
13713171 |
|||
Webcast: |
||||
About Novus Therapeutics
Novus Therapeutics, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease. Novus is headquartered in Irvine, California. For more information, please visit the company’s website at www.novustherapeutics.com.
Follow Novus Therapeutics on social media: @Novus_Thera and LinkedIn.
